Sales decreased slightly from the year-earlier period with declining demand for investment in medical appliances despite the robust sales of bio business line represented by anti-cancer immunotherapy medicine.Net loss is posted but decreased from the year-earlier period with declining sales cost and sales and admin expenses.Superior financial structure is maintained based on abundant internal liquidity and fund. Sales will be recovered with constant launch of new products amid favorable trend of bio business sector.Net loss will be posted for a while because continued R&D cost is required.Bio business line will grow as it concluded a contract with the Japanese company Medinet to transfer technology for NK cell nurturing, and with Seoul National University for producing cord blood stem cell medicines.
Headquarters
NKBIO BLDG.,66-2, SANGDAEWON 1-DONG, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO
Seongnam; Gyeonggi;
Postal Code: 462807
Contact Details: Purchase the NK Bio Co., Ltd. report to view the information.
Website: http://www.nkbio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service